

March 2026

**Dear Prospective Supporter:**

Thank you for considering supporting [Psychedelic Science Institute](#) (PSI) through the nonprofit [Psychedelic Innovation Fund](#) (PIF) at this pivotal moment for both PSI and the broader field of psychedelic medicine. Our five PSI [founders](#) bring over 30 years of combined experience in neuroscience, psychiatry and mental health, and psychedelic research, making us uniquely positioned in Southern California. In 2025, PIF raised \$1.9M to support the opening of our two TRIP Clinics in Santa Monica and Hollywood, opening six clinical trials and offering ketamine-assisted psychotherapy (KAP). We now seek \$1.5M in philanthropic bridge funding through PIF to prove our business model and position ourselves for a Q4 2026 seed round.

**Understanding the PSI/PIF Hybrid Model**

While the for-profit **PSI** operates our two clinics, conducts clinical trials, and delivers care, the nonprofit **PIF** (via Legacy Global Programs, a 501(c)(3)) supports mission-critical research, including investigator-initiated trials, education and training, and access for underserved communities. This model has proven successful in two relevant examples: **1)** the nonprofit Pacific Neuroscience Institute (PNI) Foundation and the for-profit PNI Medical Group working together over the last decade to advance neuroscience research and education, and **2)** the nonprofit MAPS (Multidisciplinary Association for Psychedelic Studies) and the for-profit Lykos (rebranded as Resilient Pharmaceuticals) working together to advance psychedelic drug development.

**2026: The Proving Year**

Long-awaited FDA approvals are anticipated for 3 psychedelic medicines in 2027 and 2028: psilocybin for depression; LSD for anxiety; MDMA for PTSD. As such, 2026 will be a critical year for psychedelic care delivery teams to prove themselves. PSI's participation in multiple Phase 3 trials positions us to be among the first clinic networks to offer these therapies upon approval. Philanthropic support in 2026 will enable us to expand our research team, scale trial enrollment, develop strategic partnerships, and establish a positive cash-flow by year-end. By successfully leveraging PIF's early philanthropic investment to prove its business model, PSI will be positioned for a seed round to support expansion with 3-5 new TRIP Clinics in Southern California.

**Flexible Support Options to Match Your Philanthropic Goals**

**For Individuals - Traditional Philanthropic Donation to PIF:** tax-deductible, no financial return.

- **Donor Advised Fund (DAF) Distribution to PIF:** direct your DAF to make a grant to PIF.
- **DAF Investment into PSI (potential for ROI):** utilize your existing DAF or establish a new DAF.

**For Foundations - Standard Foundation Grant to PIF:** credit towards 5% requirement, no financial return.

- **Recoverable Grant (potential for ROI):** via PIF investment into PSI (SAFE note with 20% discount).

**An Invitation to Partnership**

We would be grateful to have you join us at this defining moment. Your support of PIF will help validate PSI's model in 2026, and position us as the trusted, mission-driven leader in neuroplasticity-based mental health research in Southern California. Thanks for your consideration and please see below for more information.

Sincerely,



**Daniel F. Kelly, MD**  
Chief Executive Officer



**Gregory Kearns, MHA**  
Chief Strategy & Business Development Officer



**Mike Avila**  
Philanthropic Advisor

# Psychedelics as Neuroplastogens: A new paradigm in mental health and brain science

March 2026



Clinician-Built • Science-Guided • People-Focused

## Why support psychedelic research

Millions of Americans continue to struggle with depression, anxiety, addiction, PTSD, and other mental health conditions, despite access to the best available treatments.

A particularly sobering statistic is that 15–20 U.S. veterans die by suicide each day, often linked to untreated or unrecognized PTSD.

Because of this unmet need, major institutions including Johns Hopkins, Harvard, Yale, Stanford, the Dept of Veterans Affairs, and the NIH, are now rigorously studying psychedelic-assisted therapies.

**Psychedelic research is now mainstream neuroscience and psychiatry, grounded in evidence-based methodology with rigorous FDA and DEA oversight. But continued efforts by experienced teams are essential if such therapies are to be FDA approved and be responsibly integrated into modern healthcare.**

## What we've learned from modern psychedelic clinical trials

### Psychedelics are potent neuroplastogens:

By temporarily enhancing the brain's ability to form new connections, they help reorganize dysfunctional circuits, and increase adaptability. This may explain why many individuals with long-standing depression, anxiety, addiction, or PTSD have shown meaningful and lasting improvements after only 1 - 4 monitored sessions.

### They are safe in controlled settings:

Over the last 25 years, hundreds of clinical trials have shown that classic psychedelics (psilocybin, LSD, and DMT) have no addictive potential and carry extremely low physiological risk when given in structured therapeutic settings.

## What we've accomplished at PSI since July 2025

1. Opened two PSI TRIP Clinics in Santa Monica and Hollywood
2. Opened 6 industry-sponsored clinical trials for mental health conditions
3. Provided over 300 ketamine-assisted psychotherapy (KAP) sessions

Learn more about psychedelic-assisted therapy:  
[www.psychedelicsci.com/learn](http://www.psychedelicsci.com/learn)

The opportunity ahead: this neuroplasticity-based approach may enable breakthroughs across multiple conditions

- Depression
- Anxiety
- Addiction
- PTSD
- Grief and existential distress
- Traumatic brain injury
- Stroke recovery
- Cognitive decline and dementia
- Parkinson's disease
- Chronic pain

Join our PSI Founders in creating the future of mental health and neuroscience care



**Daniel Kelly, MD**  
CHIEF EXECUTIVE OFFICER



**Keith Heinzerling, MD**  
CHIEF MEDICAL & SCIENCE OFFICER



**Brooke Balliett, LMFT**  
CHIEF OPERATING OFFICER



**Micah Linton, PsyD**  
CHIEF CLINICAL & INNOVATION OFFICER



**Greg Kearns, MHA**  
CHIEF STRATEGY & BUSINESS DEVELOPMENT

[Psychedelic Innovation Fund](#)

\*PIF is a fiscal sponsorship program of Legacy Global Programs, a public 501(c)(3).